PMID- 33047883
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20240330
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Dec
TI  - Association between HLA gene polymorphisms and mortality of COVID-19: An in 
      silico analysis.
PG  - 684-694
LID - 10.1002/iid3.358 [doi]
AB  - INTRODUCTION: The emergence of SARS-CoV-2 has caused global public health and 
      economic crisis. Human leukocyte antigen (HLA) is a critical component of the 
      viral antigen presentation pathway and plays essential roles in conferring 
      differential viral susceptibility and severity of diseases. However, the 
      association between HLA gene polymorphisms and risk for COVID-19 has not been 
      fully elucidated. We hypothesized that HLA genotypes might impact on the 
      differences in morbidity and mortality of COVID-19 across countries. METHODS: We 
      conducted in silico analyses and examined an association of HLA gene 
      polymorphisms with prevalence and mortality of COVID-19 by using publicly 
      available databases. RESULTS: We found that a possible association between 
      HLA-A*02:01 and an increased risk for COVID-19. HLA-A*02:01 had a relatively 
      lower capacity to present SARS-CoV-2 antigens compared with other frequent HLA 
      class I molecules, HLA-A*11:01 or HLA-A*24:02. CONCLUSION: This study suggests 
      that individuals with HLA-A*11:01 or HLA-A*24:02 genotypes may generate 
      efficiently T-cell-mediated antiviral responses to SARS-CoV-2 compared with 
      HLA-A*02:01. The differences in HLA genotypes may potentially alter the course of 
      the disease and its transmission.
CI  - (c) 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & 
      Sons Ltd.
FAU - Tomita, Yusuke
AU  - Tomita Y
AUID- ORCID: 0000-0002-9680-7559
AD  - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto 
      University, Kumamoto, Japan.
FAU - Ikeda, Tokunori
AU  - Ikeda T
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Pharmaceutical 
      Sciences, Sojo University, Kumamoto, Japan.
AD  - Department of Medical Information Sciences and Administration Planning, Kumamoto 
      University Hospital, Kumamoto, Japan.
FAU - Sato, Ryo
AU  - Sato R
AD  - Laboratory of Stem Cell and Neuro-Vascular Biology, Genetics and Developmental 
      Biology Center, National Heart, Lung, and Blood Institute, National Institutes of 
      Health, Bethesda, Maryland, USA.
FAU - Sakagami, Takuro
AU  - Sakagami T
AD  - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto 
      University, Kumamoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201013
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 0 (HLA-A Antigens)
SB  - IM
MH  - Betacoronavirus/*immunology
MH  - COVID-19
MH  - Computer Simulation
MH  - Coronavirus Infections/genetics/immunology/*mortality/transmission
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - HLA-A Antigens/*genetics
MH  - Host-Pathogen Interactions/genetics/immunology
MH  - Humans
MH  - Linear Models
MH  - Pandemics
MH  - Pneumonia, Viral/genetics/immunology/*mortality/transmission
MH  - Polymorphism, Genetic
MH  - Prevalence
MH  - SARS-CoV-2
PMC - PMC7654404
OTO - NOTNLM
OT  - COVID-19
OT  - T cell
OT  - human leukocyte antigen
OT  - pandemic
OT  - severe acute respiratory syndrome coronavirus 2
COIS- The authors declare that there are no conflict of interests.
EDAT- 2020/10/14 06:00
MHDA- 2020/11/25 06:00
PMCR- 2020/10/13
CRDT- 2020/10/13 09:22
PHST- 2020/07/02 00:00 [received]
PHST- 2020/09/20 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
PHST- 2020/10/13 09:22 [entrez]
PHST- 2020/10/13 00:00 [pmc-release]
AID - IID3358 [pii]
AID - 10.1002/iid3.358 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2020 Dec;8(4):684-694. doi: 10.1002/iid3.358. Epub 2020 Oct 
      13.